All In Biotech

Drug Trial Radar · NCT05389267

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Last checked: Nov 20, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 5, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Laboratoires TheaIndustry
Sponsor type
Industry
First posted
May 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study purpose is to evaluate the safety of T4090.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • Kinezodianone R hydrochlorideDrug

    Eyedrops

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular and systemic adverse eventsTime frame: up to 22 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr EL-HARAZI

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.